(5Z,7E)-(1R,3S,20R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol | 96614-28-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (5Z,7E)-(1R,3S,20R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
• 英文别名: 1β,25-Dihydroxy-3-epivitamin D₃；1beta,25-dihydroxy-3-epivitamin D3/1beta,25-dihydroxy-3-epicholecalciferol；(1S,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
• CAS: 96614-28-7
• 化学式: C₂₇H₄₄O₃
• 分子量: 416.645
• InChiKey: GMRQFYUYWCNGIN-NNWVEHAGSA-N

物化性质

• 沸点：
  565.0±50.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (5Z,7E)-(1R,3S,20R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol 在 sodium tetrahydroborate 、 戴斯-马丁氧化剂 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 2.0h， 生成 (1S,3S)-5-{(Z)-2-[(1R,3aR,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-2,3,3a,6,7,7a-hexahydro-1H-inden-4-yl]-vinyl}-4-methyl-cyclohex-4-ene-1,3-diol
  参考文献：
  名称：

  Studies of vitamin D (calciferol) and its analogs. 45. Studies on the A-ring diastereomers of 1.alpha.,25-dihydroxyvitamin D3

  摘要：

  The three A-ring diastereomers 3b (compound HL), 4a (compound HJ), and 4b (compound HH), of the steroid hormone 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2-D3, 3a, compound C) have been synthesized and biologically evaluated. (R)-Carvone was converted in seven steps to the enantiomerically pure A-ring enyne 7a. Palladium-catalyzed cross-coupling of the latter with the CD-ring triflate 8 resulted in silyloxy dienyne 10, which was converted in three steps to 1beta,25-(OH)2-3-epi-D3 (4b). Oxidation of the latter with Dess-Martin reagent afforded trienone 6c, which upon reduction with sodium borohydride followed by thermolysis generated the 1alpha-epimer 4a. An identical sequence converted 1alpha,25-(OH)2-D3 to its 1beta-epimer 3b via trienone 5c. Reduction of the latter with sodium triacetoxyborohydride followed by thermal isomerization regenerated the hormone 3a. Relative competitive indices (RCls) of these analogues, which reflect their ability to bind to the chick intestinal nuclear receptor under in vitro conditions, were determined. Analogues 3b, 4a, and 4b had RCI values of 0.8 +/- 0.1 %, 24.0 +/- 4.5 %, and 0.22 +/- 0.01 %, respectively, in comparison to 1alpha,25-(OH)2-D3 whose value is 100% by definition. In addition, in vivo biological evaluation of these analogues was performed to determine their ability to induce intestinal calcium absorption (ICA) and bone calcium mobilization (BCM) in vitamin D deficient chicks. Analogue 4a was effective in stimulating ICA and BCM whereas analogues 3b and 4b exhibited little potency in eliciting these biological effects.

  DOI：

  10.1021/jo00059a048
• 作为产物：
  描述：

  (3R,5S)-1-ethynyl-3,5-dihydroxy-2-methylcyclohex-1-ene 在 Lindlar's catalyst 、 copper(l) iodide 、 bis(triphenylphosphine) palladium (Il) acetate 咪唑 、 喹啉 、 四丁基氟化铵 、 氢气 、 二乙胺 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 17.87h， 生成 (5Z,7E)-(1R,3S,20R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
  参考文献：
  名称：

  Studies of vitamin D (calciferol) and its analogs. 45. Studies on the A-ring diastereomers of 1.alpha.,25-dihydroxyvitamin D3

  摘要：

  The three A-ring diastereomers 3b (compound HL), 4a (compound HJ), and 4b (compound HH), of the steroid hormone 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2-D3, 3a, compound C) have been synthesized and biologically evaluated. (R)-Carvone was converted in seven steps to the enantiomerically pure A-ring enyne 7a. Palladium-catalyzed cross-coupling of the latter with the CD-ring triflate 8 resulted in silyloxy dienyne 10, which was converted in three steps to 1beta,25-(OH)2-3-epi-D3 (4b). Oxidation of the latter with Dess-Martin reagent afforded trienone 6c, which upon reduction with sodium borohydride followed by thermolysis generated the 1alpha-epimer 4a. An identical sequence converted 1alpha,25-(OH)2-D3 to its 1beta-epimer 3b via trienone 5c. Reduction of the latter with sodium triacetoxyborohydride followed by thermal isomerization regenerated the hormone 3a. Relative competitive indices (RCls) of these analogues, which reflect their ability to bind to the chick intestinal nuclear receptor under in vitro conditions, were determined. Analogues 3b, 4a, and 4b had RCI values of 0.8 +/- 0.1 %, 24.0 +/- 4.5 %, and 0.22 +/- 0.01 %, respectively, in comparison to 1alpha,25-(OH)2-D3 whose value is 100% by definition. In addition, in vivo biological evaluation of these analogues was performed to determine their ability to induce intestinal calcium absorption (ICA) and bone calcium mobilization (BCM) in vitamin D deficient chicks. Analogue 4a was effective in stimulating ICA and BCM whereas analogues 3b and 4b exhibited little potency in eliciting these biological effects.

  DOI：

  10.1021/jo00059a048

文献信息

• A novel and practical route to A-ring enyne synthon for 1α,25-dihydroxyvitamin D3 analogs: Synthesis of A-ring diastereomers of 1α,25-dihydroxyvitamin D3 and 2-methyl-1,25-dihydroxyvitamin D3
  作者：Katsuhiro Konno、Shojiro Maki、Toshie Fujishima、Zhaopeng Liu、Daishiro Miura、Manabu Chokki、Hiroaki Takayama

  DOI：10.1016/s0960-894x(97)10204-9

  日期：1998.1

  A novel and practical route to the A-ring enyne synthon (2), which can be versatile for a variety of A-ring analogs of 1 alpha,25-dihydroxyvitamin D3 (1), was developed. This novel method led to an improved synthesis of the A-ring diastereomers of 1, the compounds 13-15, and synthesis of the new analogs, 2-methyl-1,25-dihydroxyvitamin D3 (4) with its all possible diastereomers. The biological evaluation

  开发了一种新颖而实用的通往A环烯炔合子（2）的途径，该途径可用于多种1α，25-二羟基维生素D3（1）的A环类似物。这种新方法改进了1的A环非对映异构体，化合物13-15的合成，以及新的类似物2-甲基-1,25-二羟基维生素D3（4）及其所有可能的非对映异构体的合成。对2-甲基类似物的生物学评估表明，α-α-β-异构体的效力比1。
• Efficient synthesis and biological evaluation of all a-ring diastereomers of 1α,25-dihydroxyvitamin D3 and its 20-epimer
  作者：Toshie Fujishima、Katsuhiro Konno、Kimie Nakagawa、Mayuko Kurobe、Toshio Okano、Hiroaki Takayama

  DOI：10.1016/s0968-0896(99)00262-x

  日期：2000.1

  An improved synthesis of the diastereomers of 1alpha,25-dihydroxyvitamin D3 (1) was accomplished utilizing our practical route to the A-ring synthon. We applied this procedure to synthesize for the first time all possible A-ring diastereomers of 20-epi-1alpha,25-dihydroxyvitamin D3 (2). Ten-step conversion of 1-(4-methoxyphenoxy)but-3-ene (6), including enantiomeric introduction of the C-3 hydroxyl

  利用我们通往A环合成子的实用途径，完成了1α，25-二羟基维生素D3（1）非对映异构体的合成。我们应用此程序首次合成了20-epi-1alpha，25-dihydroxyvitamin D3（2）的所有可能的A环非对映异构体。1-（4-甲氧基苯氧基）丁-3-烯（6）的十步转化，包括通过Sharpless不对称二羟基化将C-3羟基对映体引入烯烃，提供了A环烯炔的所有四种可能的立体异构体（3）。即（3R，5R）-，（3R，5S）-，（3S，5R）-和（3S，5S）-双[（叔丁基二甲基甲硅烷基）氧基] oct-1-en-7-yne总产量。钯催化的A环合成子与20-epi CD环部分的交叉偶联（5），（E）-（20S）-de-A，B-8-（溴亚甲基）胆甾醇25-ol，然后解除保护，提供了必需的20-epi-1alpha，25-二羟基维生素D3非对映异构体（2）。根据对维生素D受体（VDR）和维生素
• Methods for detecting binding of low-molecular-weight compound and its binding partner molecule
  申请人：Esaki Keiko

  公开号：US20050084908A1

  公开（公告）日：2005-04-21

  A method for detecting the binding between a binding molecule and an immobilized low-molecular-weight compound is provided. The method comprises a step of measuring volume changes due to the binding of both compounds as an indicator. The use of immobilized low-molecular-weight compound produces highly reliable measuring results in terms of surface plasmon resonance, etc. The detection method of this invention is useful for screening for low-molecular-weight compounds that bind to binding molecules, or binding molecules that bind to low-molecular-weight compounds.

  提供了一种检测结合分子和固定低分子量化合物之间结合的方法。该方法包括测量由于两种化合物结合而产生的体积变化作为指标的步骤。使用固定低分子量化合物可在表面等离子共振等方面产生高度可靠的测量结果。本发明的检测方法对于筛选结合到低分子量化合物的结合分子或结合到结合分子的低分子量化合物非常有用。
• Enzymatic Production or Chemical Synthesis and Uses for 5,7-Dienes and UVB Conversion Products Thereof
  申请人：Slominski Andrej

  公开号：US20120258938A1

  公开（公告）日：2012-10-11

  Provided herein are steroidal compounds that are androsta-5,7-dienes or pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof and cholecalciferol derivatives hydroxylated at one or more of C1, C17, C20, C23, C24, C25, and C26 which includes pharmaceutical, cosmeceutical or nutraceutical compositions of the steroidal compounds as shown in Tables 1A, 2A and 3. Also provided is a method for producing hydroxylated metabolites of cholecalciferol via CYP11A1, CYP24, CYP27A1, or CYP27B1 enzyme systems where the hydroxylase has an activity to hydroxylate position C1 or C20 or other position of the sidechain of a secosteroid or its 5,7-dieneal precursor and the hydroxylated metabolites so produced. Methods are provided for inhibiting proliferation of either a normally or abnormally proliferating cell, for modifying immune activity, or for treating a condition associated with the proliferating or quiescent cell or immune cells by contacting the cell with or administering any of the compounds described herein.

  本文提供的是雄甾-5,7-二烯或孕甾-5,7-二烯及其紫外线B（UVB）转化产物和羟化在C1、C17、C20、C23、C24、C25和C26上的胆钙醇衍生物，其中包括表1A、2A和3中所示的雄甾类化合物的制药、化妆品或营养品组合物。同时，本文还提供了一种通过CYP11A1、CYP24、CYP27A1或CYP27B1酶系统产生羟化代谢产物的方法，其中羟化酶具有羟化分裂素或其5,7-二烯前体的侧链的C1或C20或其他位置的活性，以及由此产生的羟化代谢产物。本文还提供了一种通过接触或给予本文所述的任何化合物来抑制正常或异常增殖细胞的增殖，修饰免疫活性或治疗与增殖或静止细胞或免疫细胞相关的疾病的方法。
• PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SECONDARY HYPERPARATHYROIDISM AND THERAPEUTIC AGENTS FOR CARDIOVASCULAR COMPLICATIONS RESULTING FROM THE TREATMENT FOR SECONDARY HYPERPARATHYROIDISM.
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1402893A1

  公开（公告）日：2004-03-31

  An object of the present invention is to provide a pharmaceutical composition for the treatment of secondary hyperparathyroidism, which can reduce the risk of inducing cardiovascular complications associated with calcification, as well as a therapeutic or prophylactic agent for cardiovascular complications (e.g., arteriosclerosis, ischemic heart disease) associated with calcification resulting from the treatment of secondary hyperparathyroidism in a hemodialysis patient. The present invention provides a pharmaceutical composition for the treatment of secondary hyperparathyroidism, which comprises, as an active ingredient, a vitamin D derivative not having an inducing action on cardiovascular complications associated with calcification, as well as a therapeutic agent for cardiovascular complications associated with calcification resulting from the treatment of secondary hyperparathyroidism in a hemodialysis patient, which comprises 1α,3β-dihydroxy-20S-(3-hydroxy-3-methylbutyloxy)-9,10-seco-5,7,10(19)-pregnatriene as an active ingredient.

  本发明的目的是提供一种用于治疗继发性甲状旁腺功能亢进症的药物组合物，它可以降低诱发与钙化相关的心血管并发症的风险，同时也是一种治疗或预防血液透析患者因治疗继发性甲状旁腺功能亢进症而导致的与钙化相关的心血管并发症（如动脉硬化、缺血性心脏病）的药物。 本发明提供了一种用于治疗继发性甲状旁腺功能亢进症的药物组合物，其作为一种活性成分，包含一种对与钙化相关的心血管并发症不具有诱导作用的维生素 D 衍生物、以及一种治疗血液透析患者因治疗继发性甲状旁腺功能亢进症而引起的与钙化相关的心血管并发症的治疗剂，其活性成分包括1α,3β-二羟基-20S-(3-羟基-3-甲基丁酰氧基)-9,10-seco-5,7,10(19)-孕三烯。